CMA-676 in Treating Patients With Acute Myeloid Leukemia in First Relapse

Completed · Phase 2

Conditions studied: Leukemia

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of CMA-676 in treating patients with acute myeloid leukemia in first relapse.

Key facts

Study ID

NCT00003131

Run by

Pfizer

People needed

55

Starts

1997-02-01

Expected to finish

2002-02-01

Last updated by the study team

2012-08-22

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Arizona Cancer Center — Tucson, Arizona, United States
• Beckman Research Institute, City of Hope — Duarte, California, United States
• Sylvester Cancer Center, University of Miami — Miami, Florida, United States
• University of Chicago Cancer Research Center — Chicago, Illinois, United States
• Marlene & Stewart Greenebaum Cancer Center, University of Maryland — Baltimore, Maryland, United States
• New England Medical Center Hospital — Boston, Massachusetts, United States
• University of Michigan Comprehensive Cancer Center — Ann Arbor, Michigan, United States
• University of Nebraska Medical Center — Omaha, Nebraska, United States
• Long Island Jewish Medical Center — New Hyde Park, New York, United States
• New York Presbyterian Hospital - Cornell Campus — New York, New York, United States
• University of Pennsylvania Cancer Center — Philadelphia, Pennsylvania, United States
• University of Texas - MD Anderson Cancer Center — Houston, Texas, United States
• Fred Hutchinson Cancer Research Center — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.